JP5620392B2 - クロストリジウム・ディフィシレ胞子の発芽および伸長を阻害するための方法および組成物 - Google Patents

クロストリジウム・ディフィシレ胞子の発芽および伸長を阻害するための方法および組成物 Download PDF

Info

Publication number
JP5620392B2
JP5620392B2 JP2011534525A JP2011534525A JP5620392B2 JP 5620392 B2 JP5620392 B2 JP 5620392B2 JP 2011534525 A JP2011534525 A JP 2011534525A JP 2011534525 A JP2011534525 A JP 2011534525A JP 5620392 B2 JP5620392 B2 JP 5620392B2
Authority
JP
Japan
Prior art keywords
difficile
acid
spores
group
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011534525A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012507521A (ja
JP2012507521A5 (OSRAM
Inventor
ソーグ，ジョーゼフ
エル ソーネンシャイン，アブラハム
エル ソーネンシャイン，アブラハム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts University
Original Assignee
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts University filed Critical Tufts University
Publication of JP2012507521A publication Critical patent/JP2012507521A/ja
Publication of JP2012507521A5 publication Critical patent/JP2012507521A5/ja
Application granted granted Critical
Publication of JP5620392B2 publication Critical patent/JP5620392B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2011534525A 2008-11-03 2009-11-02 クロストリジウム・ディフィシレ胞子の発芽および伸長を阻害するための方法および組成物 Expired - Fee Related JP5620392B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11074708P 2008-11-03 2008-11-03
US61/110,747 2008-11-03
US12283508P 2008-12-16 2008-12-16
US61/122,835 2008-12-16
US15013609P 2009-02-05 2009-02-05
US61/150,136 2009-02-05
PCT/US2009/005929 WO2010062369A2 (en) 2008-11-03 2009-11-02 Methods and compositions for inhibiting clostridium difficile spore germination and outgrowth

Publications (3)

Publication Number Publication Date
JP2012507521A JP2012507521A (ja) 2012-03-29
JP2012507521A5 JP2012507521A5 (OSRAM) 2012-12-13
JP5620392B2 true JP5620392B2 (ja) 2014-11-05

Family

ID=42226300

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011534525A Expired - Fee Related JP5620392B2 (ja) 2008-11-03 2009-11-02 クロストリジウム・ディフィシレ胞子の発芽および伸長を阻害するための方法および組成物

Country Status (6)

Country Link
US (2) US9340569B2 (OSRAM)
EP (1) EP2367839A4 (OSRAM)
JP (1) JP5620392B2 (OSRAM)
AU (1) AU2009320350B2 (OSRAM)
CA (1) CA2779413A1 (OSRAM)
WO (1) WO2010062369A2 (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9079935B2 (en) 2012-08-13 2015-07-14 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Reducing risk of contracting Clostridium-difficile associated disease
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
EP4233545A3 (en) 2012-11-23 2023-10-18 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
HK1218559A1 (zh) 2013-02-04 2017-02-24 Seres Therapeutics, Inc. 抑制致病细菌生长的配方和方法
HK1218560A1 (zh) 2013-02-04 2017-02-24 Seres Therapeutics, Inc. 组成与方法
HK1220326A1 (zh) 2013-03-15 2017-05-05 Seres Therapeutics, Inc. 基於网络微生物组成和方法
WO2015076788A1 (en) 2013-11-19 2015-05-28 The Texas A&M University System Muricholic acid-based compounds as inhibitors of clostridium difficile spore germination
PT3074027T (pt) 2013-11-25 2025-03-20 Nestle Sa Composições bacterianas sinérgicas e métodos de produção e utilização das mesmas
EP3082431A4 (en) 2013-12-16 2017-11-15 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
US20170087196A1 (en) 2014-05-19 2017-03-30 Memorial Sloan-Kettering Cancer Center Methods and compositions for reducing clostridium difficile infection
GB201421071D0 (en) * 2014-11-27 2015-01-14 Univ Aston Compound for treating clostridium difficile
US20180000793A1 (en) 2015-02-06 2018-01-04 Ernesto Abel-Santos Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis
EP4066846A1 (en) 2015-11-03 2022-10-05 The Brigham & Women's Hospital, Inc. Therapeutic microbiota for the treatment and/or prevention of food allergy
MY190858A (en) * 2016-04-05 2022-05-12 Nch Corp Nutrient rich germinant composition and spore incubation method
US11701394B2 (en) 2017-08-14 2023-07-18 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
KR102323783B1 (ko) * 2017-09-22 2021-11-09 주식회사 고바이오랩 클로스트리디움 디피실레(Clostridium difficile) 성장 억제효과를 갖는 클로스트리디움 신덴스 균주
KR20200079292A (ko) 2017-10-30 2020-07-02 세레스 테라퓨틱스, 인코포레이티드 항생제 내성을 치료하기 위한 조성물 및 방법
TW202021595A (zh) 2018-08-10 2020-06-16 德商菲尼克斯製藥股份有限公司 用於預防及治療困難梭狀芽孢桿菌關聯疾病之異石膽酸或異別石膽酸及其氘化衍生物
WO2020035720A1 (en) 2018-08-17 2020-02-20 Universidad Andrés Bello Method and pharmacological composition for the prevention of recurrent infections caused by clostridium difficile.
WO2020260558A1 (en) 2019-06-27 2020-12-30 Phenex Pharmaceuticals Ag 3-modified iso-/isoallo-lithocholic acid derivatives or their homo-analogs for preventing and treating clostridioides difficile-associated diseases
US20230146782A1 (en) * 2019-08-06 2023-05-11 Du Jessica Xinyun Deoxycholic acid compounds, pharmaceutical compositions and uses thereof
CN115279889B (zh) * 2020-01-16 2024-09-10 庆应义塾 用于生成胆汁酸的组合物
CA3166211A1 (en) 2020-02-10 2021-08-19 Native Microbials, Inc. Microbial compositions and methods of use for canine enteropathy and dysbiosis
WO2023039159A2 (en) 2021-09-09 2023-03-16 Abel Santos Ernesto Inhibitors of c. difficile spore germination
WO2023079335A1 (en) 2021-11-03 2023-05-11 Universidad Andrés Bello Composition based on nystatin and vancomycin nanoparticles for the treatment of clostridioides difficile infection and prevention of recurrence
WO2023105494A1 (en) 2021-12-10 2023-06-15 Universidade Do Porto Cationic steroid compounds, method of obtaining thereof, formulations comprising thereof and their uses
CN120905091A (zh) * 2025-09-30 2025-11-07 北京常友生物科技有限公司 大肠埃希氏菌yc49及其协同拟杆菌在抑制艰难梭菌中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3708510A (en) * 1970-09-03 1973-01-02 Merck & Co Inc Amides of cholanic acid,cholenic acid,and choladienic acid
JPS62175497A (ja) * 1986-01-28 1987-08-01 Wakunaga Pharmaceut Co Ltd 胆汁酸誘導体およびその製造法
JPH0749438B2 (ja) * 1990-10-31 1995-05-31 東京田辺製薬株式会社 タウリン抱合型胆汁酸の精製方法
DE19645044A1 (de) * 1996-10-31 1998-05-07 Falk Pharma Gmbh Verwendung von Ursodeoxycholsäure zur topischen Behandlung von Entzündungserkrankungen der Schleimhäute
IL123998A (en) 1998-04-08 2004-09-27 Galmed Int Ltd Conjugates of bile salts and pharmaceutical preparations containing them
US6326364B1 (en) * 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
US7247299B2 (en) 2002-11-27 2007-07-24 Kemin Industries, Inc. Antimicrobial compounds from Bacillus subtilis for use against animal and human pathogens
WO2007111994A2 (en) * 2006-03-22 2007-10-04 Syndexa Pharmaceuticals Corporation Compounds and methods for treatment of disorders associated with er stress
US20080254010A1 (en) * 2007-03-12 2008-10-16 Joseph Myron Sasser Controlling Clostridium difficile-Associated Disease in the Gastrointestinal Tract

Also Published As

Publication number Publication date
WO2010062369A2 (en) 2010-06-03
CA2779413A1 (en) 2010-06-03
JP2012507521A (ja) 2012-03-29
WO2010062369A3 (en) 2010-10-14
AU2009320350B2 (en) 2015-09-24
US20110280847A1 (en) 2011-11-17
AU2009320350A1 (en) 2010-06-03
US20170056419A1 (en) 2017-03-02
US9340569B2 (en) 2016-05-17
EP2367839A4 (en) 2012-07-04
EP2367839A2 (en) 2011-09-28

Similar Documents

Publication Publication Date Title
JP5620392B2 (ja) クロストリジウム・ディフィシレ胞子の発芽および伸長を阻害するための方法および組成物
USRE49949E1 (en) Reducing risk of contracting clostridium-difficile associated disease
JP7523884B2 (ja) 設計された細菌組成物
JP6778747B2 (ja) 胃腸炎症性腸疾患の処置のための、ｊａｋ阻害剤化合物のプロドラッグ
AU2018318132B2 (en) Compositions and methods for treating cholestatic disease
US5204350A (en) Method of inhibiting osteoclast-mediated bone resorption by administration of n-heterocyclicalkyl-substituted phenyl derivatives
JP2014532723A (ja) 過敏性腸症候群（ｉｂｓ）及び感染症を治療するための方法
CN102548408A (zh) 治疗肝性脑病的方法
US20200262865A1 (en) Compositions and methods for treating clostridium associated diseases
WO2008121171A1 (en) Adenylyl cyclases as novel targets for antibacterial interventions
WO2008094507A2 (en) Novel fusion compounds
WO2015076788A1 (en) Muricholic acid-based compounds as inhibitors of clostridium difficile spore germination
US20210323995A1 (en) Isolithocholic acid or isoallolithocholic acid and deuterated derivatives thereof for preventing and treating clostridium difficile-associated diseases
CN112778297B (zh) 苯并噻唑类化合物及其制备方法和用途
WO2023039600A1 (en) Drug conjugates of sugar derivatives and uses thereof as senolytic agents
WO2020260558A1 (en) 3-modified iso-/isoallo-lithocholic acid derivatives or their homo-analogs for preventing and treating clostridioides difficile-associated diseases
CN117897148A (zh) 不饱和羟肟酸衍生物及其用于治疗和预防氨相关疾病或病症的用途
CN103304489B (zh) 嘧啶苯甲酰胺类化合物及其制备和应用
JPH11302176A (ja) セフェム誘導体を含有する抗ヘリコバクター剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121029

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140410

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140722

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140826

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140918

R150 Certificate of patent or registration of utility model

Ref document number: 5620392

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees